Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest S&P 500 Dividend Aristocrats Target Income UCITS ETF 11.05.2026 KNG.LN IE000SNMGYT5  900,002.00 USD  18,036,527.84   20.041  ...
-

Telekom Srbija Raises €1.95 Billion Through Landmark Eurobond Transaction, Attracting Record Demand from Global Investors

BELGRADE, Serbia--(BUSINESS WIRE)--Telekom Srbija has successfully completed its second international corporate bond issuance, raising approximately €1.95 billion through a multi-tranche offering of senior unsecured notes denominated in U.S. dollars and euros. The transaction generated exceptional investor interest, attracting total demand of USD 13.87 billion from approximately 300 leading international institutional investors, making it the largest corporate bond issuance ever executed in the...
-

Venture Global Reports First Quarter 2026 Results

ARLINGTON, Va.--(BUSINESS WIRE)--Venture Global Reports First Quarter 2026 Results...
-

Ridge Security’s RidgeBot® Wins 2026 GOVIES Award for AI-Powered Offensive Security Platform

SILICON VALLEY, Calif.--(BUSINESS WIRE)--Ridge Security today announced that its RidgeBot® platform has been named a winner in the AI-Powered Offensive Security Platform category in the 2026 Security Today GOVIES Awards. The annual GOVIES Awards recognize outstanding security products that support government and public sectors, including federal, state, and local agencies working to protect critical infrastructure and sensitive citizen data. RidgeBot was recognized for its AI-powered approach t...
-

Encoded Therapeutics Presents New Preclinical Data at ASGCT 2026 Highlighting Precision Vector Engineering Across Neurology Programs

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc. (“Encoded”), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today will present new preclinical data across two posters at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). The presentations expand the growing body of evidence supporting the company’s vector engineering platform, which is designed to achieve cell-type-selectiv...
-

Netcracker and Swisscom Receive 2026 FutureNet Award for Scaling Autonomous Network Operations

WALTHAM, Mass.--(BUSINESS WIRE)--Netcracker and its customer Swisscom have been recognized with the 2026 FutureNet Award for Autonomous Network Operations....
-

Serif Biomedicines Presents Data at ASGCT 2026 Demonstrating the Potential of Modified DNA as a New Class of Genetic Medicines

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Serif Biomedicines Presents Data at ASGCT 2026 Demonstrating the Potential of Modified DNA as a New Class of Genetic Medicines...
-

ACI Worldwide to Attend Upcoming Investor Conferences

OMAHA, Neb.--(BUSINESS WIRE)--ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, today announced that company management will participate in the following investor conferences: J.P. Morgan 2026 Global Technology, Media and Communications Conference, May 18 in Boston (President and CEO Thomas Warsop, CFO Bobby Leibrock, and SVP John Kraft) Baird 2026 Global Consumer, Technology & Services Conference, June 4 in New York City (CFO Bobby Leibrock and SVP John Kra...
-

Qnity Reports First Quarter 2026 Results, Raises Full-Year Financial Guidance

WILMINGTON, Del.--(BUSINESS WIRE)--Qnity Electronics, Inc. (“Qnity”) (NYSE: Q) today reported results for the first quarter ended March 31, 2026. “Qnity had a tremendous start to the year, outperforming our expectations and delivering our eighth consecutive quarter of strong profitable organic growth with double-digit gains in both segments,” said Jon Kemp, Qnity’s Chief Executive Officer. “These results reflect the strength of our integrated portfolio – spanning advanced chips, advanced packag...
-

Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, highlighted data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting supporting the intracerebroventricular (ICV) route of administration as a routine approach for delivering medicines, including gene therapies, to treat central nervous system (CNS) disorders. The presentation furt...